English 
Fujitsu Limited and DT Axis Corporation have entered into a partnership to support the development of software as a medical device, commonly referred to as SaMD. The two companies began their partnership on March 9 2026 through a memorandum of understanding to support research institutions and medical device developers and pharmaceutical companies who seek to bring digital health solutions from development into the market.
Therapeutic applications and AI-based imaging diagnostics in medical devices which use software as their core technology have become essential tools for disease prevention and treatment and complete health management. The development of these solutions has reached a global acceleration but Japan continues to face difficulties during its implementation. Even when strong research and technology exist, building systems that meet regulatory requirements and taking a product all the way from development to commercialization remains difficult.
Through this collaboration, Fujitsu and DT Axis plan to combine their expertise to support the entire lifecycle of programmable medical devices. That includes system design, development, regulatory approval processes, and post market operation and maintenance.
こちらもお読みください： 2026年の補助金を前にデジタルシフトを進める病院
Fujitsu will focus on system development and operational support using its experience in healthcare technology. DT Axis will work alongside 富士通 on the design, development, and operational side while also handling regulatory approvals and product commercialization. The companies are also considering the creation of a SaMD distribution platform in the future to support wider adoption of digital health technologies.
日本語